Skip to main content

Table 3 Total costs and QALYs gained

From: Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6

Alternative treatment Genotype 1 Genotype 6
Total costs (Baht) QALYs (Year) ICER (compare to palliative care) Total costs (Baht) QALYs (Year) ICER (compare to palliative care)
Palliative care 1,169,121 11.63 - 1,150,417 11.67 -
Peg 2a + RBV 747,718 13.44 Dominant 558,868 14.07 Dominant
Peg 2b + RBV 819,921 13.14 Dominant 655,697 13.69 Dominant